---
title: Reduce tremor through brain stimulation
nct_id: NCT06013956
phase: PHASE4
status: RECRUITING
sponsor: David Escobar
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06013956"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06013956"
last_fetched: "2026-05-10T14:06:52.216Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce tremor through brain stimulation

**Goal (in five words):** Reduce tremor through brain stimulation

**Official Title:** Identifying Circuit Dynamics Underlying Motor Dysfunction in Parkinson's Disease Using Real-Time Neural Control

**Trial ID:** [NCT06013956](https://clinicaltrials.gov/study/NCT06013956)

## Key Facts

- **Phase:** PHASE4
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** David Escobar
- **Target Enrollment:** 25 participants
- **Start Date:** 2023-08-29
- **Completion Date:** 2028-06-30
- **Conditions:** Parkinson Disease
- **Interventions:** Neurostimulation, Carbidopa 25/Levodopa 100Mg Tab
- **Intervention Types:** DEVICE, DRUG

## Summary For Families

The goal is to pinpoint the specific brain circuit activity that causes tremor, slowness, and other motor problems in Parkinson's so stimulation can be timed and tuned to reduce those symptoms. The approach uses deep brain stimulation targeted to the subthalamic nucleus with real-time neural control, meaning the device watches brain signals and adjusts electrical stimulation on the fly, and researchers will test how that responsive stimulation works alongside carbidopa/levodopa, the standard medication that boosts brain dopamine to improve movement. Looking for adults 18 to 80 with idiopathic Parkinson's who have been cleared as candidates for STN-DBS, can give informed consent, and can tolerate brief delays in taking their Parkinson's meds; people with secondary parkinsonism, stroke, other progressive CNS diseases, or conditions that would interfere with safety or compliance are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Key Inclusion Criteria:

* Ability to provide informed consent.
* Clinical diagnosis of idiopathic Parkinson's disease.
* Determined, as per standard of care, to be a candidate for deep brain stimulation (DBS) surgery targeting the subthalamic nucleus.
* Ability to tolerate delays in taking daily standard Parkinson's disease medications.

Key Exclusion Criteria:

* Secondary Parkinsonism, stroke, or progressive central nervous system disease other than Parkinson's disease.
* Patient has a condition that, in the opinion of the investigators, would significantly increase the risk of interfering with study compliance, safety, or outcome.
```

## Locations (1)

- Cleveland Clinic, Cleveland, Ohio, United States _(41.4995, -81.6954)_
  - David Escobar, PhD — (CONTACT) — 216-390-1907 — escobad2@ccf.org
  - Jeffrey Negrey, MA — (CONTACT) — 216-316-6896 — negreyj2@ccf.org

## Central Contacts

- David Escobar, PhD — (CONTACT) — 216-390-1907 — escobad2@ccf.org
- Jeffrey Negrey, MA — (CONTACT) — 216-316-6896 — negreyj2@ccf.org

---

*Canonical: https://parkinsonspathways.com/trial/NCT06013956*  
*HTML version: https://parkinsonspathways.com/trial/NCT06013956*  
*Source data: https://clinicaltrials.gov/study/NCT06013956*